Skip to main content
. Author manuscript; available in PMC: 2021 Dec 1.
Published in final edited form as: Circulation. 2020 Sep 16;142(22):2138–2154. doi: 10.1161/CIRCULATIONAHA.119.044805

Figure 5. RSK3 anchoring disruption attenuates pressure overload-induced cardiac hypertrophy and heart failure.

Figure 5.

A, mAKAP domain structure showing sites for binding partners that have been finely mapped and RBD and PBD peptides used in this project.4, 14, 27, 41-45 Muscle mAKAPβ is identical to neuronal mAKAPα but starting at residue 245. AC5 - adenylyl cyclase 5; MEF2 - myocyte enhancer factor-2; PLCε – phospholipase Cε; RyR – ryanodine receptor; CaN – calcineurin. B, Adult rat ventricular myocytes infected with adenovirus expressing myc-GFP or myc-GFP-RBD were cultured for 24 hours +/− 20 μmol/L phenylephrine (PE). n = 3. Cf. Figure XII in Data Supplement. C, Myocytes as in B were assayed by immunocytochemistry and morphometry. Anti-actinin – red, GFP and GFP-RBD in green, nuclei in blue. Bar - 25 μm. Bars and colored symbols indicate average mean and means of independent experiments using different myocyte preparations, respectively. n = 3. * vs. myc-GFP + PE; vs. myc-GFP + no drug. D, myc-GFP-RBD (AAV9.RBD) and myc-GFP (AAV9.GFP) were expressed in mice using AAV9 and the cardiac myocyte-specific chicken troponin T promoter.24 E, Timeline for AAV9.RBD prevention studies shown in F-J. F, Co-immunoprecipitation of mAKAPβ-RSK3 complexes using heart extracts obtained from adult RSK3−/− and AAV9.RBD and AAV9.GFP injected mice and using a pan-RSK antibody (C-20). n: RSK3−/− - 5, AAV mice - 8. G, left ventricular mass (normalized by body weight) based upon M-mode echocardiography 2 weeks post-TAC. n = 8-27. H, Wheat-germ agglutinin staining 2 weeks post-TAC. Bar - 50 μm. n = 3-6. I, left ventricular volume in systole 16-weeks post-TAC. J, gravimetric analysis 16-weeks post-TAC. I,J: n = 11-24. G-J: Bars indicate mean +/− s.e.m. * vs. GFP-TAC cohort; vs. Sham treatment for same AAV. Data for C and G-J analyzed by matched two-way ANOVA and Tukey post-hoc testing. *, p < 0.05; **,†† p < 0.01; ***,††† p < 0.001.